Ashton Katie A, Meldrum Cliff J, McPhillips Mary L, Suchy Janina, Kurzawski Grzegorz, Lubinski Jan, Scott Rodney J
Discipline of Medical Genetics, School of Biomedical Sciences, Faculty of Health, University of Newcastle and the Hunter Medical Research Institute, Newcastle, NSW, Australia.
Hered Cancer Clin Pract. 2006 May 15;4(2):94-102. doi: 10.1186/1897-4287-4-2-94.
Catechol-O-methyltransferase (COMT) is vital for the conjugation of catechol estrogens that are produced during oestrogen metabolism. The efficiency of this process varies due to a polymorphism in COMT, which changes valine to methionine (V158M). The Met genotypes slow the metabolism of catechol oestrogens, which are agents that are capable of causing DNA damage through the formation of DNA adducts and reactive oxygen species (ROS) production. The slower metabolism of catechol oestrogens results in there being a higher circulating concentration of these oeastrogens and consequently greater probability of DNA damage. To determine whether metabolic inefficiencies of oeastrogen metabolism are associated with the development of malignancy in hereditary non-polyposis colorectal cancer (HNPCC), we studied the V158M polymorphism in COMT in a large cohort of 498 HNPCC patients from Australia and Poland that were either mutation positive (n = 331) or negative (n = 167) for mismatch repair (MMR) gene mutations (hMLH1 or hMSH2). HNPCC is a familial predisposition to colorectal cancer (CRC) and extracolonic cancers that include endometrial cancer.Using Real Time PCR, the COMT V158M polymorphism was examined and its association with disease expression, age of diagnosis of cancer, mutation status and mutation type was assessed in the HNPCC MMR mutation positive and negative groups. This study showed that the V158M polymorphism had no association with disease risk in the HNPCC MMR mutation positive population. However, the polymorphism was significantly associated with endometrial/ovarian cancer risk in HNPCC MMR mutation negative patients (p = 0.002). The heterozygous (Val/Met) genotype was associated with an increased risk of developing endometrial/ovarian cancer whereas the homozygous mutant (Met/Met) showed a decreased risk. The results suggest heterosis, where there is an apparent greater effect of the heterozygous state in this dichotomous trait. In conclusion, this study shows that the COMT V158M polymorphism alters the risk of developing endometrial/ovarian cancer in patients that adhere to the Amsterdam HNPCC criteria but do not have a DNA mismatch repair gene mutation.
儿茶酚-O-甲基转移酶(COMT)对于雌激素代谢过程中产生的儿茶酚雌激素的结合至关重要。由于COMT基因多态性,该过程的效率会有所不同,这种多态性会使缬氨酸变为甲硫氨酸(V158M)。甲硫氨酸基因型会减缓儿茶酚雌激素的代谢,儿茶酚雌激素是一类能够通过形成DNA加合物和产生活性氧(ROS)而导致DNA损伤的物质。儿茶酚雌激素代谢减缓导致这些雌激素的循环浓度升高,从而增加DNA损伤的可能性。为了确定雌激素代谢效率低下是否与遗传性非息肉病性结直肠癌(HNPCC)的恶性肿瘤发生有关,我们在来自澳大利亚和波兰的498名HNPCC患者的大型队列中研究了COMT基因的V158M多态性,这些患者错配修复(MMR)基因突变(hMLH1或hMSH2)检测结果为阳性(n = 331)或阴性(n = 167)。HNPCC是一种患结直肠癌(CRC)和包括子宫内膜癌在内的结肠外癌症的家族性倾向。使用实时聚合酶链反应(Real Time PCR)检测COMT基因的V158M多态性,并在HNPCC MMR突变阳性和阴性组中评估其与疾病表达、癌症诊断年龄、突变状态和突变类型的关联。这项研究表明,V158M多态性与HNPCC MMR突变阳性人群的疾病风险无关。然而,该多态性与HNPCC MMR突变阴性患者的子宫内膜癌/卵巢癌风险显著相关(p = 0.002)。杂合子(Val/Met)基因型与患子宫内膜癌/卵巢癌的风险增加有关,而纯合突变体(Met/Met)显示风险降低。结果提示杂种优势,即在这种二分性状中杂合状态具有明显更大的效应。总之,这项研究表明,COMT基因的V158M多态性会改变符合阿姆斯特丹HNPCC标准但无DNA错配修复基因突变患者患子宫内膜癌/卵巢癌的风险。